JP2025517336A5 - - Google Patents
Info
- Publication number
- JP2025517336A5 JP2025517336A5 JP2024568191A JP2024568191A JP2025517336A5 JP 2025517336 A5 JP2025517336 A5 JP 2025517336A5 JP 2024568191 A JP2024568191 A JP 2024568191A JP 2024568191 A JP2024568191 A JP 2024568191A JP 2025517336 A5 JP2025517336 A5 JP 2025517336A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263342548P | 2022-05-16 | 2022-05-16 | |
| US63/342,548 | 2022-05-16 | ||
| PCT/US2023/022243 WO2023224912A1 (en) | 2022-05-16 | 2023-05-15 | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517336A JP2025517336A (ja) | 2025-06-05 |
| JP2025517336A5 true JP2025517336A5 (enExample) | 2026-05-22 |
Family
ID=86764360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568191A Pending JP2025517336A (ja) | 2022-05-16 | 2023-05-15 | 転移性去勢抵抗性前立腺癌を二重特異性抗ｐｓｍａ×抗ＣＤ３抗体を単独で、又は抗ＰＤ－１抗体と組み合わせて治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250304714A1 (enExample) |
| EP (1) | EP4525992A1 (enExample) |
| JP (1) | JP2025517336A (enExample) |
| KR (1) | KR20250010677A (enExample) |
| CN (1) | CN119421723A (enExample) |
| AU (1) | AU2023272836A1 (enExample) |
| CA (1) | CA3253070A1 (enExample) |
| IL (1) | IL316751A (enExample) |
| MX (1) | MX2024014019A (enExample) |
| WO (1) | WO2023224912A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026024863A2 (en) * | 2024-07-24 | 2026-01-29 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| JP7215997B2 (ja) * | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 |
| CA3136892A1 (en) * | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methods of treating renal cancer with an anti- psma/cd3 antibody |
| AR118720A1 (es) * | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| EP3986933A1 (en) * | 2019-06-21 | 2022-04-27 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
| WO2022060878A1 (en) * | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
-
2023
- 2023-05-15 WO PCT/US2023/022243 patent/WO2023224912A1/en not_active Ceased
- 2023-05-15 EP EP23730657.6A patent/EP4525992A1/en active Pending
- 2023-05-15 CA CA3253070A patent/CA3253070A1/en active Pending
- 2023-05-15 CN CN202380046439.5A patent/CN119421723A/zh active Pending
- 2023-05-15 JP JP2024568191A patent/JP2025517336A/ja active Pending
- 2023-05-15 IL IL316751A patent/IL316751A/en unknown
- 2023-05-15 US US18/865,527 patent/US20250304714A1/en active Pending
- 2023-05-15 KR KR1020247041541A patent/KR20250010677A/ko active Pending
- 2023-05-15 AU AU2023272836A patent/AU2023272836A1/en active Pending
-
2024
- 2024-11-12 MX MX2024014019A patent/MX2024014019A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230270894A1 (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| TW202005985A (zh) | 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法 | |
| US20090220510A1 (en) | Specific binding proteins and uses thereof | |
| CN111629788A (zh) | 用拮抗性抗-pd-1抗体治疗癌症的方法 | |
| KR20200032189A (ko) | 항-ctla-4 항체 및 이의 용도 | |
| JP7545983B2 (ja) | 抗ｖｅｇｆ抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いてがんを治療する方法 | |
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2024009998A (ja) | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 | |
| JP7160533B2 (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| CA3014461C (en) | Chimeric canine anti-cd20 antibody | |
| WO2019183253A1 (en) | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate | |
| US20240299601A1 (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| EP3814379A1 (en) | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate | |
| WO2023217268A1 (zh) | 抗tim-3抗体与抗pd-1抗体的药物组合 | |
| JP2025509567A5 (enExample) | ||
| JP2025502061A5 (enExample) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| US20260062500A1 (en) | Bispecific antibody targeting hk2 and cd3 for the treatment of prostate cancer | |
| JP2024525870A (ja) | 抗ｐｌａ２ｒ自己抗体媒介膜性腎症の治療 | |
| US20240010729A1 (en) | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer | |
| WO2024183622A1 (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| RU2026105219A (ru) | Способы лечения метастатического кастрационно-резистентного рака предстательной железы с помощью биспецифических антител к psma/cd28 | |
| RU2024129390A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕЙ ЭПИТЕЛИОИДНОЙ САРКОМЫ С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХАНТИТЕЛ ПРОТИВ MUC16 x CD3 САМИХ ПО СЕБЕ ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ ПРОТИВ PD-1 | |
| TW202513554A (zh) | 用於治療前列腺癌之組合療法 | |
| WO2025256641A1 (zh) | 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤 |